HC Wainwright Issues Pessimistic Forecast for Cognition Therapeutics (NASDAQ:CGTX) Stock Price

Cognition Therapeutics (NASDAQ:CGTX) had its price target lowered by equities researchers at HC Wainwright from $6.00 to $5.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Cognition Therapeutics’ Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.07) EPS.

A number of other brokerages have also commented on CGTX. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the company from $1.00 to $1.50 in a research note on Thursday, December 19th. Chardan Capital reduced their price objective on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 21st. Finally, Brookline Capital Management upgraded shares of Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $7.50.

Cognition Therapeutics Price Performance

Shares of CGTX opened at $0.46 on Monday. Cognition Therapeutics has a one year low of $0.34 and a one year high of $2.95. The company has a market cap of $19.08 million, a PE ratio of -0.47 and a beta of 1.03. The stock has a 50-day moving average of $0.57 and a 200-day moving average of $0.55.

Cognition Therapeutics (NASDAQ:CGTX) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same period last year, the company posted ($0.27) earnings per share. Analysts expect that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Hedge Funds Weigh In On Cognition Therapeutics

A number of hedge funds have recently bought and sold shares of CGTX. BIOS Capital Management LP purchased a new stake in shares of Cognition Therapeutics in the fourth quarter valued at about $4,208,000. Voss Capital LP bought a new stake in Cognition Therapeutics in the 4th quarter worth about $351,000. Sigma Planning Corp increased its stake in Cognition Therapeutics by 211.6% in the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after buying an additional 417,300 shares during the last quarter. Virtu Financial LLC purchased a new stake in Cognition Therapeutics in the 3rd quarter valued at about $27,000. Finally, Two Sigma Investments LP lifted its position in shares of Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after buying an additional 42,321 shares in the last quarter. 43.35% of the stock is owned by hedge funds and other institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.